Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: EPZM
- Previous Close: $12.80
- 50 Day Moving Average: $11.32
- 200 Day Moving Average: $10.03
- 52-Week Range: $58,011,000.00 - $7.02
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.98
- P/E Growth: 0.00
- Market Cap: $742.54M
- Outstanding Shares: 58,011,000
- Beta: 2.24
- Net Margins: -1,205.01%
- Return on Equity: -41.56%
- Return on Assets: -34.78%
Companies Related to Epizyme:
- Current Ratio: 17.35%
- Quick Ratio: 17.35%
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
Where is Epizyme's stock going? Where will Epizyme's stock price be in 2017?
8 equities research analysts have issued 12 month target prices for Epizyme's stock. Their forecasts range from $17.00 to $39.00. On average, they anticipate Epizyme's stock price to reach $25.00 in the next year.
When will Epizyme announce their earnings?
Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
Who owns Epizyme stock?
Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.08%), Palo Alto Investors LLC (5.23%), Deerfield Management Co. (2.76%), Foresite Capital Management II LLC (2.63%), Franklin Resources Inc. (2.00%) and State Street Corp (1.88%). Company insiders that own Epizyme stock include Andrew E Singer, Bay City Capital Fund V Co-Inv, David M Mott, Peter Tai-Ching Ho, Robert A Copeland and Robert J Gould.
Who sold Epizyme stock? Who is selling Epizyme stock?
Epizyme's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Foresite Capital Management II LLC and Foresite Capital Management III LLC. Company insiders that have sold Epizyme stock in the last year include Andrew E Singer and Robert A Copeland.
Who bought Epizyme stock? Who is buying Epizyme stock?
Epizyme's stock was purchased by a variety of institutional investors in the last quarter, including Deerfield Management Co., State Street Corp, Palo Alto Investors LLC, J. Goldman & Co LP, Russell Investments Group Ltd., Dimensional Fund Advisors LP and Metropolitan Life Insurance Co. NY. Company insiders that have bought Epizyme stock in the last two years include Bay City Capital Fund V Co-Inv, David M Mott and Peter Tai-Ching Ho.
How do I buy Epizyme stock?
Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Epizyme stock cost?
One share of Epizyme stock can currently be purchased for approximately $12.80.